開拓藥業-B(9939.HK)漲4% 福瑞他恩治療脱髮完成首例患者入組 正式啟動III期臨牀試驗
格隆匯1月3日丨開拓藥業-B(9939.HK)現漲4%報12.8港元,最新市值50億港元。開拓藥業昨日公佈,其自主研發、潛在全球同類首創的外用藥物福瑞他恩(KX-826)用於治療男性雄激素性脱髮(“AGA”)患者的中國註冊性III期臨牀試驗於2021年12月31日完成首例患者入組及給藥。2021年11月24日,公司宣佈中國國家藥品監督管理局(NMPA)同意開展該項III期臨牀試驗。福瑞他恩是全球首個進入註冊性III期臨牀試驗用於AGA治療的雄激素受體(AR)拮抗劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.